Bio
I am a physician-scientist who has established a human translational research group that fosters the development of both laboratory immunologists, and clinical translational researchers. Allogeneic hematopoietic cell transplantation (alloHCT) cures blood cancer via beneficial graft-v-tumor immunity. Our overall research goal is to augment GVT while preventing detrimental graft versus host disease (GVHD). The Miklos lab pioneered protein microarray technologies to discover clinically relevant allogeneic antibodies, especially those targeting H-Y antigens following sex mismatched transplantation. Our discovery that allogeneic HY antibodies develop in association with chronic GVHD revealed a critical B cell role in chronic GVHD pathogenesis and our clinical trials established cGVHD therapeutic benefits using anti-B cell drugs rituximab and ibrutinib. We developed high-throughput sequencing of the B and T cell immune receptor thereby enabling: 1) lymphoid disease quantification, 2) detailed B and T cell donor reconstitution kinetics, and 3) clonal analysis of antigen specific responses following allo-HCT.
Immunotherapy is revolutionizing cancer treatment I am the Clinical Director of our Cancer Cell Therapy Program developing and evaluating the most promising chimeric antigen T-cell (CAR-T) therapies leading over 10 ongoing clinical trials. CAR-T genetically modifies the patient's T lymphocytes to target their cancer. Thus far, the most successful CAR-T have targeted B cell antigens CD19, CD20, CD22, and BCMA, and our ongoing trials are treating patients with relapsed/refractory leukemia, lymphoma, and multiple myeloma.
Clinical Focus
- Cancer > Blood and Marrow Transplant
- Cancer > Hematology
- Chimeric Antigen Receptor Therapy (CAR-T)
- Blood and Marrow Transplantation
- Graft vs Host Disease
- Lymphoma
- Leukemia
- Multiple Myeloma
- Hematology/Oncology
Academic Appointments
-
Associate Professor - Med Center Line, Medicine - Blood & Marrow Transplantation
-
Member, Stanford Cancer Institute
Administrative Appointments
-
Associate Chief Blood and Marrow Transplantation, Stanford University (2020 - 2021)
-
Clinical Director Cancer Cell Therapy, Stanford University (2016 - Present)
-
Medical Director of Stanford Cellular Therapeutics and Transplantation Laboratory, Stanford University (2011 - 2016)
Honors & Awards
-
Phi Betta Kappa, University of Notre Dame (1987)
-
Alpha Omega Alpha, Yale Medical School (1995)
-
Predoctoral Fellow, Howard Hughes Medical Institute (1989-1993)
-
Medical Scientist Training Fellow, NIH (1993-1995)
-
Clinical Investigator Training Program Scholar, Harvard Medical School (2001-2003)
Boards, Advisory Committees, Professional Organizations
-
Member, American Society of Transplantation and Cell Therapy (1998 - Present)
-
Member, American Society of Clinical Oncology (2014 - Present)
-
Member, American Society of Hematology (1998 - Present)
Professional Education
-
Board Certification: American Board of Internal Medicine, Hematology (2002)
-
Board Certification, American Board of Internal Medicine, Hematology (2019)
-
Medical Education: Yale University Office of the Registrar (1995) CT
-
Fellowship: Dana Farber Cancer Institute Hematology Oncology Fellowship (2001) MA
-
Residency: Brigham and Women's Hospital Harvard Medical School (1998) MA
-
Internship: Brigham and Women's Hospital Harvard Medical School (1996) MA
-
B.S., University of Notre Dame (1987)
-
M.D., Yale University Medical School (1995)
-
Ph.D., Yale University, Genetics (1995)